A Phase I, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics and Food Effect of BVL-GSK098 Administered as Single and Multiple Oral Doses to Healthy Volunteers
Latest Information Update: 20 Jan 2023
At a glance
- Drugs Alpibectir (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; First in man
- Sponsors BioVersys
- 21 Jun 2022 Results presented in a BioVersys Media Release.
- 21 Jun 2022 Status changed from recruiting to completed, according to a BioVersys media release.
- 09 Oct 2021 Planned End Date changed from 30 Jun 2021 to 1 Jun 2022.